Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (December 2020)

59 slides from Marinus Pharmaceuticals's investor presentation, Dec 7, 2020

  1. Slide 1: Corporate Overview 2020

    NASDAQ: MRNS@MarinusPharma Corporate Overview 2020

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private

  3. Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABAA Receptors

    Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABAA Receptors Ganaxolone a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders. GNX is designed to modulate both synaptic and extrasynaptic GABAA rec

  4. Slide 4: Corporate Strategy

    Corporate Strategy Evaluation of IV and Oral Opportunities Building Upon Status Epilepticus (SE) Maximizing Value for Orphan Epilepsies Leveraging GNX Molecule Expand clinical opportunities from refractory status epilepticus (RSE) to broader SE market Initiate commercial plan Create a global develop

  5. Slide 5: Ganaxolone Development Pipeline

    Ganaxolone Development Pipeline

  6. Slide 6: Status Epilepticus Indication

    Status Epilepticus Indication

  7. Slide 7: Status Epilepticus: Definition and Epidemiology

    Status Epilepticus (SE): Definition and Epidemiology Background Continuous seizures lasting >5 min SE is the second most common neurologic emergency in the U.S. 1 Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdraw

  8. Slide 8: Goals of a New Therapy for the Treatment of SE

    Goals of a New Therapy for the Treatment of SE Established Status Epilepticus (ESE) Refractory Status Epilepticus (RSE) Medically induced Coma Super Refractory Status Epilepticus (SRSE) 1st line2nd line 3rd line Benzodiazepine Administered IV AED’s (antiepileptic drugs) IV GNX IV Anesthetics ©2020 M

  9. Slide 9: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Human PD – EEG changes2 Ganaxolone targets the extrasynaptic receptor, is associated with high brain concentrations, and delivers a rapid onset of action Brain and plasma concentration after gana

  10. Slide 10: Phase 2 SE Trial Design

    Phase 2 SE Trial Design Evaluate IV ganaxolone in refractory SE patients SE Patients Diagnosis of convulsive or non-convulsive SE Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Screening Treatment Period Loading DoseMaintenanceTaper Post-treatment Follow-up 24

  11. Slide 11: Patient Demographics of Phase 2 Trial

    Patient Demographics of Phase 2 Trial 17 patients enrolled 8 males, 9 females Mean age: 57 years old (range: 23-88) History of Epilepsy 7 (41%) yes, 10 (59%) no Types of SE 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE→NCSE Mean # of failed first-and-second line IV AEDs (including benzodiazepines) Mean # o

  12. Slide 12: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through 24 hours from infusion initiation (investigator determination) No escalation to additional IV AEDs or IV anes

  13. Slide 13: PK/PD Relationship and Rationale for Target Dose

    PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups Seizure Burden Reduction Occurred Rapidly in All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hoursOnly High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presen

  14. Slide 14: IV Ganaxolone Safety Summary

    IV Ganaxolone Safety Summary 10 SAEs in 6 patients (also included in AEs) 50 AEs in 16 patients 2 related in 2 patients 2 severe sedation 8 non-related in 4 patients 1 Death due to withdrawal of life support 1 Respiratory depression 1 Bowel perforation (fatal) 1 Sepsis (fatal) 1 Fall 1 Loss of consc

  15. Slide 15: Overview of U.S. Phase 3 RSE RAISE Trial Design

    Overview of U.S. Phase 3 RSE RAISE Trial Design Trial design•Randomized, placebo-controlled (adjunctive to standard-of-care) clinical trial Target patient population•Status epilepticus patients (n=124) who have failed benzodiazepines and ≥ 2 IV AEDs Dosing 36-hour infusion followed by a 12-hour tape

  16. Slide 16: RSE Phase 3 RAISE Clinical Planning

    RSE Phase 3 RAISE Clinical Planning Treatment PeriodFollow-up Period Initiation Status Site identification through initiation underway Drug and placebo supply ready for shipment to sites Daily S CHours 0 -24 Day 2 Hours 24-36 Hours 36-48 Daily hours Weeks 1,2,3 & 4 Currently recruiting patients R EB

  17. Slide 17: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    RAISE Trial Sites Standard of Care Progression to IV Anesthesia Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than one 2nd-line IV AEDs 100 %of Patients Progressing to 3rd-l

  18. Slide 18: BARDA Contract – Refractory Status Epilepticus

    BARDA Contract – Refractory Status Epilepticus Key Contract Parameters BARDA to contribute $21 million in base contract to support the Phase 3 RAISE clinical trial in RSE and preclinical studies of ganaxolone in nerve agent exposure animal models. BARDA may contribute up to an additional $30 million

  19. Slide 19: Commercial Opportunity

    Commercial Opportunity M’ARINUS PHARMACEUTICALS

  20. Slide 20: Quantifying the Significant Clinical and Economic Burden of RSE

    Quantifying the Significant Clinical and Economic Burden of RSE The Phase 3 trial of ganaxolone in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation to IV anesthetics. Treatment with IV anesthetics has been reported to lead to increased length of hospital admis

  21. Slide 21: RSE is a Neurological Emergency With Significant Unmet Need

    RSE is a Neurological Emergency With Significant Unmet Need in a Severely Impaired and Costly Patient Population Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (4

  22. Slide 22: Potential Launch Into the Hospital Setting

    Potential Launch Into the Hospital Setting Designed to be Driven by Data, Customer Collaboration & Protocolization of Ganaxolone in RSE Critical Success Factors for RSE Launch Clinical and Economic Evidence Society Guideline & Account Access Experienced Hospital Sales • Ph3 data to support clinical

  23. Slide 23: Additional Commercial Opportunities Along SE Continuum

    Additional Commercial Opportunities Along SE Continuum Potential to leverage existing hospital sales force to address > 3x patient population in ESE & SRSE ESETT DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 ©2020 Marinus Pharma

  24. Slide 24: Potential Expansion of Ganaxolone into Established Status Epilepticus

    Potential Expansion of Ganaxolone into Established Status Epilepticus (ESE) Emergency RoomICU Tertiary Center ICU Unique Environment: -No EEG -Risk of rapid escalation of care -Convulsive patients: new dosing paradigm – bolus and short infusion time (2-24 hours)

  25. Slide 25: Established Status Epilepticus – Use of Ganaxolone in Emergency Room

    Established Status Epilepticus – Use of Ganaxolone in Emergency Room Pilot: N = 4-5 per cohort Failed benzodiazepine Open bolusIV ganaxolone infusion Standard of care IV AED Blinded: N = 40 per arm Failed benzodiazepine 1:1 bolus Placebo bolus IV ganaxolone: Placebo Standard of care IV AED Screening

  26. Slide 26: Genetic Epilepsy Franchise

    Genetic Epilepsy Franchise

  27. Slide 27: CDKL5 Deficiency Disorder

    CDKLS Deficiency Disorder M’ARINUS PHARMACEUTICALS

  28. Slide 28: CDKL5 Deficiency Disorder (CDD)

    CDKL5 Deficiency Disorder (CDD) Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, treatment refractory seizures, & severe neuro-developmental delay Most can’t walk, talk or care for themselves Suffer from scoliosis, visual impairment

  29. Slide 29: Global Phase 3 Pivotal Trial Design

    Global Phase 3 Pivotal Trial Design Historical Control 8 weeks Baseline 6 weeks Titration 4 weeks Maintenance 13 weeks Titration 4 weeks Open-Label Phase Double-Blind PhaseOpen-Label Phase Trial Details Evaluated the use of oral ganaxolone in children and young adults Global, double-blind, placebo-c

  30. Slide 30: Subject Baseline Clinical Characteristics & Prior/Concomitant Medications

    Subject Baseline Clinical Characteristics & Prior/Concomitant Medications Baseline seizure burden and AED history highlights unmet need

  31. Slide 31: Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction

    Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction and Secondary Endpoint in Caregiver Impression of Change Median Percent Reduction 28-day Frequency of Major Motor Seizures = 29.7%* p = 0.002** Caregiver Global Impression of Change in Seizure Intensity / Duration (CGI-CSID) 3032.2%

  32. Slide 32: Marigold Cumulative Response Curve

    Marigold Cumulative Response Curve ** ** *p < 0.05 * * * * * Ganaxolone Placebo % of Patients 40 20 0 50 *Fisher's Exact Test % Reduction in Major Motor Seizure Frequency

  33. Slide 33: Consistent Efficacy Signal Across the Broader CDD Population

    Consistent Efficacy Signal Across the Broader CDD Population Ganaxolone demonstrated a similar efficacy signal across multiple subgroups related to baseline demographics and seizure frequency. –Supports beneficial effect in the U.S. patient population Percent Reduct ion in M edian M ajor M ot or Sei

  34. Slide 34: Phase 3 Safety Summary

    Phase 3 Safety Summary Treatment Emergent Adverse Events (TEAE) Serious Treatment Emergent Adverse Events Preferred Term Placebo (n=51) Ganaxolone (n=50) Any Serious TEAE, n (%) 5 (9.8) 6 (12.0) Bronchitis 0 (0.0) 1 (2.0) Rhinovirus Infection 0 (0.0) 1 (2.0) Urinary Tract Infection 0 (0.0) 1 (2.0) P

  35. Slide 35: Durable Seizure Improvements in the Open Label Extension

    Ganaxolone’s Potential to Provide Durable Seizure Improvements in the Open Label Extension Seizures associated with CDD are often refractory to treatment with existing AEDs and improvements may be short-lived (<3 months)1 Preliminary analysis* of the open-label extension (OLE) provides insights into

  36. Slide 36: Average Ganaxolone Levels Correlate with Seizure Reduction

    Average Ganaxolone Levels Correlate with Seizure Reduction Logarithms of plasma GNX level and percentage change in major motor seizure frequency were negatively correlated Patients in the Medium and High GNX level groups had an average GNX concentration of 120 ng/mL and a median 43% reduction in sei

  37. Slide 37: Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies

    Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies Dosing regimen: Marigold Study was the first Phase 3 study of ganaxolone to evaluate three times a day (TID) dosing Predicted pharmacokinetic (PK) curves for TID and two times a day (BID) dosing demonstrate increase trough GNX levels which

  38. Slide 38: Ganaxolone Formulation Work in Progress for Second Generation Candidate

    Ganaxolone Formulation Work in Progress for Second Generation Candidate Exploring opportunities to improve bioavailability and PK profile Potential expansion into new indications and into new therapeutic areas Targeting IV-to-oral step down for patients that may benefit from continued therapy IV Dos

  39. Slide 39: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex M’ARINUS PHARMACEUTICALS

  40. Slide 40: Allo-S as Potential Biomarker Across Various Genetic Epilepsies

    Allo-S as Potential Biomarker Across Various Genetic Epilepsies Scientific literature associates genetic orphan epilepsies with neurosteroid imbalances Marinus has identified abnormal neurosteroid levels in several patient subtypes These findings lead to stratification by Allo-S biomarker in clinica

  41. Slide 41: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex CauseDefect or mutation of TSC1 and/or TSC2 genes Symptoms abnormalities Prevalence~25K-40K refractory TSC patients in the U.S.* TreatmentsLimited approved treatments Mechanistic RationalePotential neurosteroid deficiency1 1 diMichele, et al, J. Neuro Neurosurg Psychiatry,

  42. Slide 42: Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone

    Unmet Need in TSC Epilepsy and Scientific Rationale for Ganaxolone Epilepsy present in ~90% of individuals affected with TSC Existing treatments fail to control seizures in ~60% of individuals with TSC-associated epilepsy Uncontrolled seizures, especially early in life, may lead to developmental del

  43. Slide 43: Phase 2 TSC Trial Design

    PART A Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Baseline Period PART B Open-Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol OLE Period 2-week taper upon GNX discontinuation Screening Visit Baseline Treatment Visit (if not c

  44. Slide 44: PCDH19 Related Epilepsy

    PCDH19 Related Epilepsy

  45. Slide 45: PCDH19-Related Epilepsy

    PCDH19-Related Epilepsy CauseInherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early-onset seizures, cognitive and sensory impairment, and psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Prevalence Affects ~10K children

  46. Slide 46: Seizure Reduction Observed in PCDH19-RE Phase 2 Trial

    Seizure Reduction Observed in PCDH19-RE Phase 2 Trial in Patients with Low Allo Levels 25% decrease in median seizure frequency reported in Phase 2 (n=11) Stratification of patients by baseline plasma Allo levels identifies a subpopulation with expected improved efficacy on GNX When comparing seizur

  47. Slide 47: Biomarker Stratified Proof of Concept Study in PCDH19

    Biomarker Stratified Proof of Concept (POC) Study in PCDH19 Primary efficacy analyses will be conducted using this cohort PCDH19 (all-patients) n~20-22 Low Allo-S Biomarker + High Allo-S Biomarker - R 1:1 R 1:1 Placebo Ganaxolone Up to 600 mg 3x/day Placebo Ganaxolone Up to 600 mg 3x/day Ganaxolone

  48. Slide 48: Commercial Opportunity

    Commercial Opportunity M’ARINUS PHARMACEUTICALS

  49. Slide 49: Commercialization Preparedness

    Commercialization Preparedness Executing research with Payers and Physicians around TPP / Value Proposition Identifying organizational needs for field resources, systems and processes Developing plans to scale up Advocacy, Scientific Affairs and Commercial teams Readying supply chain to support pack

  50. Slide 50: Our Oral Franchise Model is Driven by Ganaxolone Scientific Rationale

    Our Oral Franchise Model is Driven by Ganaxolone Scientific Rationale and Unmet Need in Debilitating Rare Epilepsy Disorders Given CDKL5 and TSC patient seizure burden, overlap of CDKL5 and TSC prescribers, and common market dynamics, we group both indications under a franchise go to market CDKL5 De

  51. Slide 51: Our Goal: Build a Sustainable Franchise in Rare Epilepsy

    Our Goal: Build a Sustainable Franchise in Rare Epilepsy Opportunity to expand treated population through future clinical development Phase 2 (TSC) 40,000 patients2 Rare Epilepsy ~163,0005 Phase 3 (CDKL 5) ~5,500 patients1 80-90% refractory3 50-60% refractory3 20-40% refractory4 ~ 4,400 CDKL 5 Patie

  52. Slide 52: Key Findings from Recently Conducted Market Research

    Key Findings from Recently Conducted Market Research Show that Ganaxolone is Well Suited for Broad Clinical Adoption Across Indications Mechanism of Action Ganaxolone’s extrasynaptic mechanism of action well understood and viewed as differentiable TPP Reactions Many HCPs are excited about the opport

  53. Slide 53: Intellectual Property

    Intellectual Property

  54. Slide 54: Multiple Layers Of Potential Protection

    Multiple Layers Of Potential Protection Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in US and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in US.

  55. Slide 55: Thank You

    NASDAQ: MRNS@MarinusPharma Thank You

  56. Slide 56: Appendix

    Appendix M'ARINUS PHARMACEUTICALS

  57. Slide 57: Details on Baseline Patient Characteristics for Phase 2 SE Trial

    Details on Baseline Patient Characteristics for Phase 2 SE Trial 1 Low Vascular No NCSE LAC, LEV 200mg (200-600mg) 2 Low Unknown Yes NCSE fPHT, LEV 1,000mg (1000-3000mg) 3 Low Vascular No NCSE LOR, LAC, LEV 600mg (200-600mg) 4 Low Vascular No NCSE LOR, LAC, LEV 600mg (200-600mg) 5 Low Tumor No CSE L

  58. Slide 58: Subject Baseline Demographics & Country Enrollment in Marigold Study

    Subject Baseline Demographics & Country Enrollment in Marigold Study (CDD) Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2) Ethnicity, n (%) Hispanic or Latino 6 (11.8) 4 (8.0) 10

  59. Slide 59: Responder Analysis – Marigold Study

    Responder Analysis – Marigold Study 100 % of Patients p=0.001* 6057.1% Ganaxolone Placebo Percent Reductions in Major Motor Seizure Frequency 40p=0.064* 23.5%24.5% 20 9.8%10.2% 0 3.9% 75% *Fisher's Exact Test Reduction in Major Motor Seizure Frequency

Marinus Pharmaceuticals — Investor Presentation (December 2020) on 6ix